What oral estradiol dose is equivalent to a transdermal patch delivering 0.075 mg per day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Transdermal to Oral Estradiol Conversion

A transdermal patch delivering 0.075 mg/day estradiol is approximately equivalent to 2 mg oral micronized estradiol daily, though direct dose equivalence is imperfect due to different pharmacokinetic profiles.

Pharmacokinetic Rationale

The conversion is not straightforward because oral and transdermal estradiol have fundamentally different absorption and metabolism patterns:

  • Oral estradiol undergoes first-pass hepatic metabolism, resulting in 5-fold higher estrone levels and 10- to 20-fold higher estrone sulfate compared to transdermal administration at comparable doses 1

  • Transdermal estradiol bypasses hepatic first-pass metabolism, producing an estradiol-to-estrone ratio approximating 1:1 (similar to premenopausal physiology), whereas oral administration creates excessive estrone elevation 2

Evidence-Based Conversion

Research directly comparing these routes demonstrates:

  • A 0.05 mg/day transdermal patch produces steady-state estradiol levels of approximately 35 pg/mL with minimal fluctuation (0.65) 3

  • 2 mg oral micronized estradiol produces average steady-state concentrations of 418 pg/mL with large fluctuations (3.68), but trough levels 24 hours post-dose are similar to transdermal steady-state levels 2, 3

  • The 0.075 mg transdermal dose in Turner syndrome patients produced estradiol levels of 114 ± 31 pg/mL, while 2 mg oral produced 46 ± 15 pg/mL (though measured at different time points) 4

Therefore, 0.075 mg transdermal roughly corresponds to 2 mg oral estradiol when considering clinical efficacy for symptom control and gonadotropin suppression, despite vastly different peak concentrations 2.

Clinical Considerations

Key Differences to Anticipate:

  • Metabolic effects differ: Oral estradiol increases SHBG, thyroid-binding globulin, triglycerides, and C-reactive protein due to hepatic first-pass effect 1

  • Thrombotic risk differs: Transdermal estradiol does not increase VTE risk even in high-risk women, while oral estradiol does (RR 2.07 for oral estrogen/progestin vs. 0.82 for transdermal) 5

  • Bioavailability varies: Oral estradiol has significantly higher bioavailability (61% higher) than transdermal gel formulations 6

When Converting:

  • Start with 2 mg oral estradiol daily as the equivalent dose
  • Titrate based on symptom response rather than strict dose equivalence 1
  • Consider measuring estradiol levels if symptoms don't improve with escalating doses, particularly after route changes 1
  • Expect different side effect profiles: oral may cause more nausea initially; transdermal may cause skin reactions

Important Caveats

There is no perfect 1:1 conversion because the routes produce different hormonal profiles. The 0.075 mg transdermal to 2 mg oral conversion is based on:

  • Comparable gonadotropin suppression 2
  • Similar clinical efficacy for vasomotor symptoms
  • Trough oral levels approximating transdermal steady-state levels

However, oral administration exposes tissues to much higher peak estradiol and persistently elevated estrone metabolites 3. The clinical significance of these differences for long-term outcomes remains incompletely characterized, though cardiovascular and thrombotic safety clearly favor transdermal administration 1, 5.

Related Questions

What is the appropriate way to switch from a transdermal estradiol patch to oral estradiol tablets, including dose conversion and monitoring?
What estradiol level should be achieved while using a transdermal estradiol patch (e.g., Estradot)?
What oral estradiol dose is equivalent to a 0.05 mg twice‑weekly transdermal estradiol patch?
What oral estradiol dose is equivalent to the Climara transdermal patch delivering 0.06 mg (60 µg) estradiol per 24 hours?
What are the differences between the transdermal estradiol patch (Climara 0.025 mg) and the estradiol topical gel (Estrogel 0.06 %) for estrogen therapy?
Can clonidine be added safely to a patient already taking atorvastatin 10 mg daily and losartan 50 mg daily?
Can I use Bactroban (mupirocin) for my penile infection after topical ketoconazole (Ketaderm) and clotrimazole have failed?
Please review the laboratory panel of a patient with chronic kidney disease stage 4 (estimated glomerular filtration rate (eGFR) ≈ 16 mL/min/1.73 m²) that shows elevated serum creatinine, elevated blood urea nitrogen (BUN), low serum carbon dioxide (CO₂) indicating metabolic acidosis, borderline low calcium, and otherwise normal electrolytes.
What does "aspirational" mean when referring to guideline dates such as the 2026 European Respiratory Society (ERS) and 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) references?
What is the best non‑stimulant medication for a 38‑year‑old woman with a prior diagnosis of ADHD who does not tolerate stimulant medications?
What is the most likely diagnosis and appropriate work‑up for a patient with low mean corpuscular hemoglobin (MCH) 26.4 pg, low mean corpuscular hemoglobin concentration (MCHC) 30.5 g/dL, elevated red cell distribution width (RDW) 19.3 %, increased platelet count 479 ×10⁹/L, and normal hemoglobin, hematocrit, and mean corpuscular volume (MCV)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.